Nason, G. J.
Kuhathaas, K.
Anson-Cartwright, L.
Jewett, M. A. S.
O’Malley, M.
Sweet, J.
Hansen, A.
Bedard, P.
Chung, P.
Hahn, E.
Warde, P.
Hamilton, R. J.
Article History
Received: 27 January 2021
Accepted: 8 May 2021
First Online: 12 May 2021
Declarations
:
: Robert Hamilton: Advisory Board—Bayer, Amgen, Janssen, Astellas. Research Funding—Bayer (ARASENS trial), Janssen (SPARTAN trial). Speaking Honoraria—Abbvie. Meeting Travel—Roche. Sources of Funding: None. No other conflicts of interest to declare.
: Approval was received from the institutional review board at the Princess Margaret Cancer Centre (CAPCR # 14-7509).